WO2020101596A3 - Composition de capsule comprenant du sunitinib - Google Patents

Composition de capsule comprenant du sunitinib Download PDF

Info

Publication number
WO2020101596A3
WO2020101596A3 PCT/TR2019/050579 TR2019050579W WO2020101596A3 WO 2020101596 A3 WO2020101596 A3 WO 2020101596A3 TR 2019050579 W TR2019050579 W TR 2019050579W WO 2020101596 A3 WO2020101596 A3 WO 2020101596A3
Authority
WO
WIPO (PCT)
Prior art keywords
sunitinib
capsule composition
capsule
composition
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2019/050579
Other languages
English (en)
Other versions
WO2020101596A2 (fr
Inventor
Ali Turkyilmaz
Yuksel TOPALOGLU
Ali Ihsan SECKIN
Irem Yenice
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arven Ilac Sanayi ve Ticaret AS
Original Assignee
Arven Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arven Ilac Sanayi ve Ticaret AS filed Critical Arven Ilac Sanayi ve Ticaret AS
Publication of WO2020101596A2 publication Critical patent/WO2020101596A2/fr
Publication of WO2020101596A3 publication Critical patent/WO2020101596A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une capsule comprenant du sunitinib et au moins un liant. La présente invention concerne en outre un procédé de préparation de ladite composition.
PCT/TR2019/050579 2018-08-10 2019-07-16 Composition de capsule comprenant du sunitinib Ceased WO2020101596A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2018/11687 2018-08-10
TR201811687 2018-08-10

Publications (2)

Publication Number Publication Date
WO2020101596A2 WO2020101596A2 (fr) 2020-05-22
WO2020101596A3 true WO2020101596A3 (fr) 2020-07-09

Family

ID=70730567

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2019/050579 Ceased WO2020101596A2 (fr) 2018-08-10 2019-07-16 Composition de capsule comprenant du sunitinib

Country Status (1)

Country Link
WO (1) WO2020101596A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113440495B (zh) * 2021-07-14 2022-07-12 北京鑫开元医药科技有限公司 苹果酸舒尼替尼胶囊及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013160916A1 (fr) * 2012-04-25 2013-10-31 Hetero Research Foundation Dispersion solide de malate de sunitinib
CN104069076A (zh) * 2013-03-29 2014-10-01 浙江九洲药业股份有限公司 一种无定型的舒尼替尼与pvp的组合物
CN105434399A (zh) * 2015-12-24 2016-03-30 湖南尔康制药股份有限公司 一种肾细胞癌治疗药物舒尼替尼-PLGA/Fe3O4复合微球及其制备方法
WO2017181187A1 (fr) * 2016-04-15 2017-10-19 Exelixis, Inc. Procédé de traitement du cancer à cellules rénales à l'aide de n-(4-(6,7-diméthoxyquinolin-4-yloxy) phényl)-n'-(4-fluorophény)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
EP3539536A1 (fr) * 2018-03-15 2019-09-18 MH10 Spolka z ograniczona odpowiedzialnoscia Composition pharmaceutique de sunitinib ou de son sel dans sa forme polymorphe i

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013160916A1 (fr) * 2012-04-25 2013-10-31 Hetero Research Foundation Dispersion solide de malate de sunitinib
CN104069076A (zh) * 2013-03-29 2014-10-01 浙江九洲药业股份有限公司 一种无定型的舒尼替尼与pvp的组合物
CN105434399A (zh) * 2015-12-24 2016-03-30 湖南尔康制药股份有限公司 一种肾细胞癌治疗药物舒尼替尼-PLGA/Fe3O4复合微球及其制备方法
WO2017181187A1 (fr) * 2016-04-15 2017-10-19 Exelixis, Inc. Procédé de traitement du cancer à cellules rénales à l'aide de n-(4-(6,7-diméthoxyquinolin-4-yloxy) phényl)-n'-(4-fluorophény)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
EP3539536A1 (fr) * 2018-03-15 2019-09-18 MH10 Spolka z ograniczona odpowiedzialnoscia Composition pharmaceutique de sunitinib ou de son sel dans sa forme polymorphe i

Also Published As

Publication number Publication date
WO2020101596A2 (fr) 2020-05-22

Similar Documents

Publication Publication Date Title
EP3875458A4 (fr) Composé de type diphényle, son intermédiaire, son procédé de préparation, sa composition pharmaceutique et ses applications
SG11202110376XA (en) Heteroaryl derivative, method for producing the same, and pharmaceutical composition comprising same as effective component
WO2018109174A3 (fr) Anticorps anti-il-11
EP4512399A3 (fr) Formes à l'état solide de tafamidis et leurs sels
WO2019020602A3 (fr) Luminophore et composition
WO2018109170A3 (fr) Anticorps il-11ra
IL285651A (en) Anti-trem2 antibodies, preparations containing them and their uses
WO2018006074A3 (fr) Composés et méthodes permettant de moduler la fonction de l'arn
GB201918321D0 (en) Geopolymer composition, a method for preparing the same and its uses
WO2019120234A3 (fr) Composé fonctionnant comme inhibiteur de protéine bromodomaine, et composition
MY200328A (en) Kinase inhibitors and uses thereof
EP4327880A3 (fr) Forme à l'état solide de succinate de ribociclib
WO2017214458A3 (fr) Anticorps anti-cd98 et conjugués anticorps-médicament
WO2020131586A3 (fr) Méthodes d'identification de néo-antigènes
WO2017160116A3 (fr) Nouveau composé pour inhiber la nicotinamide phosphoribosyltransférase et composition contenant le nouveau composé
IL284800A (en) Methods, uses and compositions
EP4413979A3 (fr) Compositions pharmaceutiques pour des applications anesthésiologiques
MX382609B (es) Nuevas formulaciones y composiciones de cannabis en comprimidos y métodos para su elaboración.
WO2018127612A3 (fr) Compositions comprenant un extrait de plante lespedeza
WO2019194773A3 (fr) Combinaison contenant de la linagliptine et de la metformine
MY201777A (en) Crystalline forms of 3-substituted 1,2,4-oxadiazole
WO2016006974A3 (fr) Nouveaux dérivés triazolopyrimidinone ou triazolopyridinone et leur utilisation
WO2020123330A3 (fr) Anticorps anti-alpha-synucléine et leurs utilisations
WO2016006975A3 (fr) Nouveaux dérivés imidazotriazinone ou imidazopyrazinone et leur utilisation
WO2015095659A3 (fr) Composition de dispersion solide d'indirubine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19884360

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19884360

Country of ref document: EP

Kind code of ref document: A2